Document is current

Any future updates will be listed below

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

Crossref DOI link: https://doi.org/10.1007/s12325-022-02054-z

Published Online: 2022-02-14

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark